HDAC9 and idiopathic pulmonary fibrosis: Another drug that is actually used and considered feasible in IPF and lung cancer-IPF patients is vantictumab, which influences Wnt signaling and is in Phase I clinical trials for the role of inhibitor of lung fibrosis [254,255] Indeed, a preclinical study demonstrated the anti-fibrotic effects of CG-745, a histone deacetylase (HDAC) inhibitor, in bleomycin mouse models.